美國國家醫(yī)學(xué)院 （NAM） 今天宣布在其年會期間選舉 90 名正式會員和 10 名國際會員。當(dāng)選為學(xué)院成員被認為是健康和醫(yī)學(xué)領(lǐng)域的最高榮譽之一，旨在表彰表現(xiàn)出杰出專業(yè)成就和對服務(wù)承諾的個人。

“這批新成員代表了健康和醫(yī)學(xué)領(lǐng)域最杰出的研究人員和領(lǐng)導(dǎo)者，他們?nèi)〉昧酥卮笸黄疲I(lǐng)導(dǎo)了應(yīng)對重大公共衛(wèi)生挑戰(zhàn)，并促進了健康公平，”NAM 總裁 Victor J. Dzau 說。“他們的專業(yè)知識對于支持 NAM 解決我們今天面臨的緊迫健康和科學(xué)挑戰(zhàn)的工作是必要的。我很榮幸歡迎這些受人尊敬的人加入美國國家醫(yī)學(xué)院。

新成員由現(xiàn)任成員通過一個程序選出，該程序旨在表彰為醫(yī)學(xué)科學(xué)、醫(yī)療保健和公共衛(wèi)生的進步做出重大貢獻的個人。NAM 的組織章程確保了成員中的人才多樣性，該章程規(guī)定至少四分之一的成員是從衛(wèi)生專業(yè)以外的領(lǐng)域選出的——例如，來自法律、工程、社會科學(xué)和人文科學(xué)等領(lǐng)域。新當(dāng)選的成員使 NAM 的成員總數(shù)達到 2,400 多人，其中包括近 200 名國際成員。

美國國家醫(yī)學(xué)科學(xué)院最初由美國國家科學(xué)院于 1970 年成立，前身為醫(yī)學(xué)研究所，致力于解決健康、科學(xué)、醫(yī)學(xué)和相關(guān)政策方面的關(guān)鍵問題，并激發(fā)跨部門的積極行動。NAM 與美國國家科學(xué)院和美國國家工程院合作，為國家提供獨立、客觀的分析和建議，并開展其他活動來解決復(fù)雜問題并為公共政策決策提供信息。美國國家科學(xué)院、工程院和醫(yī)學(xué)院還鼓勵教育和研究，表彰對知識的杰出貢獻，并增加公眾對 STEMM 的理解。NAM 成員當(dāng)選后承諾自愿為國家科學(xué)院的活動提供服務(wù)。

美國國家醫(yī)學(xué)科學(xué)院新當(dāng)選的正式成員及其選舉引文是：

Toyin Ajayi，醫(yī)學(xué)博士、哲學(xué)碩士，紐約布魯克林 Cityblock Health 首席執(zhí)行官成為國際知名的初級保健先驅(qū)，專注于改善具有復(fù)雜健康/社會需求的低收入和邊緣化人群的結(jié)果。她是 Cityblock Health 的首席執(zhí)行官兼聯(lián)合創(chuàng)始人，Cityblock Health 是一個成熟且領(lǐng)先的全國性模式，旨在為服務(wù)不足的人群提供初級保健轉(zhuǎn)型和護理整合。

Zoltan Pierre Arany，醫(yī)學(xué)博士，博士， 費城賓夕法尼亞大學(xué)佩雷爾曼醫(yī)學(xué)院醫(yī)學(xué)系心臟病學(xué)教授 Samuel Bellet。闡明圍產(chǎn)期心肌?。ㄔ挟a(chǎn)婦后死亡的主要原因）的原因，并在定量代謝研究解決心血管疾?。òㄐ牧λソ吆鸵葝u素抵抗）的機制方面發(fā)揮世界領(lǐng)導(dǎo)作用。

Paola Arlotta 博士， 馬薩諸塞州劍橋市哈佛大學(xué)干細胞和再生生物學(xué)系 Golub 家族教授。在開發(fā)和應(yīng)用強大的基于干細胞的人腦模型、腦類器官方面做出了開創(chuàng)性的工作，并為理解人腦形成過程和人類神經(jīng)系統(tǒng)疾病做出了基礎(chǔ)性貢獻。

Carlos L. Arteaga，醫(yī)學(xué)博士，達拉斯德克薩斯大學(xué)西南醫(yī)學(xué)中心腫瘤學(xué)項目教授兼副院長，西蒙斯綜合癌癥中心主任。發(fā)現(xiàn) TGFβ 在乳腺癌進展中的作用，以及人表皮生長因子受體 2 （HER2） 和 PI3K 突變以及 FGFR1 擴增在乳腺癌耐藥性中的作用，為 PI3K 抑制劑的創(chuàng)新新輔助試驗和批準(zhǔn)奠定基礎(chǔ)。他是美國癌癥研究協(xié)會 （American Association for Cancer Research） 的第一位西班牙裔美國主席。

Tracy L. Bale，博士， 安舒茨基金會女性綜合身心健康捐贈主席;精神病學(xué)系教授;科羅拉多大學(xué)奧羅拉分校代際壓力與健康主任和精神病學(xué)性別差異研究系主任。開創(chuàng)性地確定了整個生命周期中的壓力會增加神經(jīng)精神疾病風(fēng)險的新生物學(xué)機制，開創(chuàng)性地將細胞過程轉(zhuǎn)化為人類疾病中的生物標(biāo)志物，包括參與后代神經(jīng)發(fā)育的生殖細胞水平的生物效應(yīng)，以及她對弱勢群體的變革性參與和包容。

Jonathan F. Bean，醫(yī)學(xué)博士、公共衛(wèi)生碩士，哈佛醫(yī)學(xué)院物理醫(yī)學(xué)與康復(fù)系教授;以及波士頓弗吉尼亞州波士頓醫(yī)療保健系統(tǒng)新英格蘭老年研究教育和臨床中心主任。在將多學(xué)科、精準(zhǔn)醫(yī)學(xué)原則應(yīng)用于康復(fù)方面進行變革性工作，為老年人/退伍軍人重新概念化了醫(yī)療保健系統(tǒng)和實踐，以采用個性化、數(shù)據(jù)驅(qū)動的健康老齡化方法，以實現(xiàn)前所未有的護理人員支持和減少跌倒，使他們能夠保持獨立性、生產(chǎn)力和福祉在社區(qū)中。

Nina Bhardwaj，醫(yī)學(xué)博士，博士， Waldman 癌癥研究主席;醫(yī)學(xué)教授（血液學(xué)和腫瘤內(nèi)科）和泌尿?qū)W;紐約市西奈山伊坎醫(yī)學(xué)院疫苗和細胞治療實驗室免疫治療主任和醫(yī)學(xué)主任。開創(chuàng)了人類樹突狀細胞亞群的發(fā)現(xiàn)和功能，確定了影響癌癥和病毒免疫的抗原呈遞的交叉呈遞途徑，并建立了它們在人類中的有效佐劑活性，這些關(guān)鍵發(fā)現(xiàn)為首次批準(zhǔn)基于細胞的癌癥疫苗奠定了基礎(chǔ)。

Maria Elena Bottazzi 博士，兒科、分子病毒學(xué)和微生物學(xué)系教授;以及休斯頓貝勒醫(yī)學(xué)院國家熱帶醫(yī)學(xué)院高級副院長兼部門主任。擔(dān)任熱帶和新發(fā)疾病微生物學(xué)家、疫苗學(xué)家、全球健康倡導(dǎo)者以及無專利開源 COVID-19 疫苗技術(shù)的共同創(chuàng)造者。她開創(chuàng)并領(lǐng)導(dǎo)了強大的傳染病疫苗組合的發(fā)展，以應(yīng)對對世界上最貧困人口產(chǎn)生不成比例影響的疾病。

Kathryn H. Bowles, PhD, RN, FAAN, FACMI, professor and van Ameringen Chair in Nursing Excellence, University of Pennsylvania School of Nursing; and vice president and director, Center for Home Care Policy and Research, VNS Health, Philadelphia. For work in accelerating the implementation of a learning health system via rigorous evidence in transitional care and advances in health information technologies. Bowles and her team have developed and commercialized a decision support tool for discharge planning to identify patients in need of post-acute care services. Her work with sepsis survivors resulted in a new ICD-10 code for sepsis aftercare.

Chiquita Brooks-LaSure, MPP, administrator, Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services, Washington, D.C. For her long career of service in health policy, during which she helped to draft and implement the Affordable Care Act while working in Congress and the Obama administration. She is the first Black woman to lead the Centers for Medicare and Medicaid Services.

Robert D. Bullard, PhD, distinguished professor and director, urban planning and environmental policy, Bullard Center for Environmental and Climate Justice, Texas Southern University, Houston. For extraordinary vision, groundbreaking research, and sustained leadership to identify and end injustices affecting vulnerable people and places disproportionately harmed by pollution and climate change. Known as “the father of environmental justice,” he has long led the charge to dismantle systems and structures that create and maintain inequality.

Jason A. Burdick, PhD, Bowman Endowed Professor, BioFrontiers Institute and the department of chemical and biological engineering, University of Colorado, Boulder. For innovative biomaterials and biofabrication techniques for application in in vitro models of biological and disease processes, as well as therapies for the repair and regeneration of injured musculoskeletal and cardiovascular tissues.

Jennifer D. Carlson, PhD, professor, Sanford School of Social and Family Dynamics, and founding director, Center for the Study of Guns in Society, Arizona State University, Tempe. For leadership in fostering understanding of how guns shape American lives, including those who survive gun violence, police who enforce the country’s complex gun laws, gun retailers on the front lines of gun purchasing, and the people who own and carry guns.

Bob S. Carter, MD, PhD, William and Elizabeth Sweet Professor of Neurosurgery, Harvard Medical School and Massachusetts General Hospital, Boston. For contributions to neurosurgery, neuro-oncology, central nervous system gene-/cell-based therapies, including the creation of CAR T cells against human glioblastoma (hGBM), discovery of extracellular vesicles in hGBM, and “first in man” use of induced pluripotent stem cell derived dopaminergic neurons for Parkinson’s disease.

Stephen Jacob Chanock, MD, director, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Md. For being an international leader in cancer genetics, identifying susceptibility alleles in more than a dozen cancers. He has awards for first describing clonal mosaicism and its relationship to cancer and aging. He has created and fostered international consortia on BRCA genetics and COVID-19.

Christopher G. Chute, MD, DrPH, Bloomberg Distinguished Professor of Health Informatics, Schools of Medicine, Public Health, and Nursing, Johns Hopkins University, Baltimore. For long-standing leadership and innovation in representation of clinical and phenotyping data in computable form that has significantly influenced the structure and content of electronic health records and their reuse in translational research as real-world data, building on his basic work in biomedical ontology, clinical classification, and fair interoperability standards.

Janine Austin Clayton, MD, FARVO, director, Office of Research on Women’s Health, National Institutes of Health, Bethesda, Md. For advancing policy, program, and practice innovations to improve the health of all women by catalyzing integration of sex/gender factors across the biomedical research continuum to galvanize discovery and equity. She is the architect of NIH’s high-impact 2016 Sex as a Biological Variable policy, a landmark upgrade for research.

I. Glenn Cohen, JD, deputy dean and James A. Attwood and Leslie Williams Professor of Law, Harvard Law School, Harvard University, Cambridge, Mass. For scholarship on bioethics and health law in the U.S. and globally, including pioneering work on AI/big data and health, abortion, reproductive rights and technologies, therapeutic use of psychedelics, and LGBTQ rights. He is unequaled in organizing major scholarly collaborations, and is a leading bioethical voice in the media.

Lisa M. Coussens, PhD, FAACR, FAIO, professor and chair, department of cell, developmental, and cancer biology, and deputy director for basic and translational research, Knight Cancer Institute, Oregon Health & Science University, Portland. For paradigm-shifting mechanistic studies on inflammation and cancer that identified B cell and myeloid cell significance in fostering solid tumor progression and hindering therapeutic responses. Coussens subsequently conducted proof-of-concept clinical studies, successfully demonstrating that targeting B cell or myeloid-based molecular pathways yield systemic and tumor immune reprogramming that fosters anti-tumor immunity.

Lindsey A. Criswell, MD, MPH, DSc, director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Md. For defining genetic and epigenetic contributions to development of autoimmune rheumatic disorders and their relationship to specific serologic and clinical phenotypes and to genetic ancestry of patients. Her work has transformed understanding of the pathogenesis of lupus, rheumatoid arthritis, Sjögren’s disease, and related diseases.

Chinazo Opia Cunningham, MD, MS, commissioner, New York State Office of Addiction Services and Supports, New York City. For being a national and international leader in the conceptualization of addiction, the development of evidence-driven programmatic innovations in treatment, and the rigorous evaluation of program effectiveness. As commissioner of New York State’s Office of Addiction Services and Supports, she leads one of the largest addiction treatment systems in the U.S.

Leemore Dafny, PhD, Bruce V. Rauner Professor of Business Administration, Harvard Business School; and professor of public policy, Harvard Kennedy School, Boston. For path-breaking work in illuminating where health care markets succeed and fail, including powerful insights regarding market consolidation, strategic decisions of market participants, and policy solutions to market failures. Her research on competition in health care appears in leading journals, and she has testified and provided advice to government agencies and congressional committees at the highest levels.

Teresa A. Davis, PhD, professor, department of pediatrics, Children’s Nutrition Research Center, Baylor College of Medicine, Houston. For international expertise on the nutritional regulation of growth, having identified fundamental mechanisms by which nutrients regulate muscle protein synthesis and growth, with direct implications for improving lean growth and health of infants. She is a global leader on protein and amino acid requirements.

David Dranove, PhD, Walter McNerney Distinguished Professor of Health Industry Management, Kellogg School of Management, Northwestern University, Evanston, Ill. For foundational insights on how health care markets work and how they affect patients generally, vulnerable populations, health care delivery, costs, and health outcomes. His work has changed scholarly and public understanding of health care markets and shaped policies toward hospitals, health insurance, physician practices, and pharmaceuticals.

Patricia C. Dykes, PhD, MA, RN, research program director, Center for Patient Safety, Research, and Practice, Brigham and Women’s Hospital; and professor of medicine, Harvard Medical School, Boston. For being an internationally recognized nurse scientist and biomedical informatician who has developed, integrated into practice, and broadly disseminated innovative, cost-effective health information technology tools that engage patients and families in fall prevention, markedly reducing patient falls — the leading cause of injury-related death for those 65 and older.

Peter Joseph Embí, MD, MS, FACP, FACMI, FIAHSI, professor of biomedical informatics and medicine and chair, department of biomedical informatics, Vanderbilt University Medical Center, Nashville, Tenn. For being a pioneering physician-scientist whose career bridges health care, research, public health, and biomedical informatics. His thought leadership and research led to the field of clinical research informatics, real-world evidence generation, the safe and effective use of AI in health care, and data-driven learning health systems that improve health and care.

Alicia Fernandez, MD, professor of medicine, University of California, San Francisco. For seminal health services research elucidating the impact of language and literacy barriers on patient outcomes and experience of care that highlights the challenges facing millions with limited English proficiency, and for effectively championing workforce diversity and health equity through high-impact research and program development.

Erol Fikrig, M.D., Waldemar Von Zedtwitz Professor of Medicine and professor of microbial pathogenesis and epidemiology; and section chief, infectious disease, department of internal medicine, Yale School of Medicine, New Haven, Conn. For mechanistic studies that led to an FDA-approved outer surface protein A-based human Lyme disease vaccine. He elucidated how arthropod-transmitted pathogens use vector proteins to infect mammals. These efforts led to an experimental vaccine to induce host resistance to tick bites, and therefore prevent Lyme disease — a new strategy for combatting infections.

Silvia C. Formenti, MD, FAACR, FACR, FASTRO, professor of radiation oncology and medicine and chair, department of radiation oncology, Weil Cornell Medicine; and radiation oncologist-in-chief, New York-Presbyterian Hospital, New York City. For introducing a paradigm shift in our understanding of focal radiotherapy by demonstrating that it can convert the tumor into an “in situ,” individualized vaccine, conferring systemic immunity. Her work has opened a new field in radiation biology.

Monika Kumari Goyal, MD, MSCE, professor of pediatrics and emergency medicine, George Washington University; and endowed chair for Women in Science and Health and co-director, Center for Translational Research, Children’s National Hospital, Washington, D.C. For being a national leader in research in pediatric firearm injury prevention. Her research has shed a spotlight on the burden of firearm violence on child health. She is also a leading pediatric equity scientist, developing interventions that have led to mitigation of health care disparities.

Marcia Carmen Haigis, PhD, professor, department of cell biology, Harvard Medical School, Boston. For leadership and pioneering studies in cellular metabolism, elucidating how metabolites contribute to normal physiology, aging, cancer, and anti-tumor immune control. Her discoveries informed how diet and age alter metabolite interactions, leading to disease.

Scott David Halpern, MD, PhD, MBioethics, John M. Eisenberg Professor in Medicine, professor of medical ethics and health policy and of epidemiology, and director, Palliative and Advanced Illness Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia. For making seminal contributions to improving care near the end of life by combining conceptual and empirical work. Through trenchant ethical analyses and leadership of the field’s largest clinical trials, he has challenged old paradigms of serious illness decision-making and demonstrated how low-cost, scalable interventions can improve care quality and outcomes.

Joseph Heitman, MD, PhD, James B. Duke Professor and chair, department of molecular genetics and microbiology, Duke University School of Medicine, Durham, N.C. For pioneering yeast chemical genetics approaches to discover FKBP12 and TOR as targets of the immunosuppressive chemotherapeutic drug rapamycin widely used in transplant, cardiology, and oncology. He discovered unisexual reproduction and roles in evolution and pathogenesis of eukaryotic microbes illuminating impact on diversity, outbreaks, and drug resistance.

Sally Lynn Hodder, MD, FIDSA, associate vice president of clinical and translational research, professor of medicine, and preeminent scholar chair, School of Medicine, West Virginia University Health Sciences, Morgantown. For accomplishments as an infectious diseases physician and researcher. She is a leader in the design and conduct of clinical trials, particularly among underserved rural and underrepresented populations. She is an expert in HIV treatment and prevention, rural health, addiction research, mentorship of young investigators, and engagement of community in research.

David Huang, MD, PhD, Wold Family Endowed Chair in Ophthalmic Imaging, associate director, and director of research, Casey Eye Institute; and professor of ophthalmology and biomedical engineering, Oregon Health & Science University, Portland. For co-inventing optical coherence tomography (OCT), which has transformed the diagnosis and treatment of eye diseases and the studies of cardiovascular, neurological, and neoplastic diseases. He developed methods to use OCT and OCT angiography in glaucoma, diabetic retinopathy, and macular degeneration, the leading causes of blindness.

Shawna Veleura Hudson, PhD, vice chancellor for dissemination and implementation science, Rutgers Health, and professor of family medicine and community health, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, N.J. For seminal work to address vital U.S. health system implementation challenges for vulnerable populations. Her research shapes policy and practice to integrate care of cancer and other chronic illnesses for patients and families in the context of their communities during the critical transitions between specialty and primary care, and long-term cancer survivorship

Nola M. Hylton, PhD, professor of radiology and biomedical imaging, University of California, San Francisco. For the earliest development of breast MRI technology, the modern quantitative MRI techniques for breast cancer diagnosis and therapy guidance through development of MRI industrywide NIST-supported standards; leadership of multiple national network multicenter NCI trials; and development of globally commercialized (Hologic) software, improving the health of millions of women globally.

Reshma Jagsi, MD, DPhil, Lawrence W. Davis Professor and chair, department of radiation oncology, Emory University School of Medicine, Atlanta. For pioneering empirical research that has identified targetable drivers of disparities in cancer outcomes and within the medical profession, particularly for women. Her work to develop and evaluate innovative interventions to promote equity has established new areas of investigation in oncology and prompted policy changes by institutions, funders, and professional societies.

Yishi Jin, PhD, professor, department of neurobiology, School of Biological Sciences, University of California, San Diego, La Jolla. For groundbreaking discoveries on phylogenetically conserved mechanisms that drive synapse formation and that underlie central nervous system regeneration, providing fundamental knowledge and molecular targets which inform therapeutic strategies for ameliorating the effects of neuronal injury and degeneration.

Peter Anthony Jones, PhD, DSc (hon), president of the graduate school; chief scientific officer; professor, department of epigenetics; and co-leader, Stand Up to Cancer Epigenetics Dream Team; Van Andel Institute, Grand Rapids, Mich. For mechanistically linking DNA methylation gene expression and differentiation. His seminal discovery that 5 azanucleosides could change immortalized embryonic cells into muscle cells opened the field of epigenetics, was an early example of cellular reprogramming, and led to FDA approval of DNA methyltransferase inhibitors (DNMTis) for treatment of hematological malignancies.

Joseph Keawe‘aimoku Kaholokula, PhD, professor and chair, department of Native Hawaiian health, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu. For pioneering evidence-based interventions using Indigenous cultural values and practices to improve cardiovascular, diabetes, and obesity disparities for thousands of Native Hawaiians and Pacific Islanders (NH/PI). He spans science and practice, provides direction to health care systems serving NH/PI, advocates for NH/PI, and develops NH/PI scientists.

Christine Laine, MD, MPH, editor-in-chief, Annals of Internal Medicine, American College of Physicians; and professor of medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia. For expanding the influence of the Annals of Internal Medicine and the American College of Physicians by addressing issues such as firearms and gun violence, reproducible research, misinformation, reproductive health, equitable health care, and scientific misconduct.

Kenneth M. Langa, MD, PhD, Cyrus Sturgis Professor of Medicine, department of internal medicine and Institute for Social Research, University of Michigan, Ann Arbor. For being a global leader in the study of aging. His research has better defined the prevalence, outcomes, and population trends of cognitive impairment and dementia in the U.S. and around the world, and has allowed identification of the myriad costs of these conditions on patients, families, governments, and societies.

Haifan Lin, PhD, Eugene Higgins Professor of Cell Biology and professor of genetics, of dermatology, and of obstetrics, gynecology, and reproductive sciences; and director, Yale Stem Cell Center, Yale School of Medicine, New Haven, Conn. For making key contributions to the validation of two hallmark stem cell theories: asymmetric division and niche hypotheses. He discovered the only gene family (argonaute/piwi genes) known to be essential for stem cell maintenance in both animals and plants. He discovered millions of small noncoding RNAs called piRNAs and established a new paradigm of genome regulation.

Massimo Loda, MD, David D. Thompson Professor and chair, department of pathology and laboratory medicine, Weill Cornell Medicine; professor emeritus of pathology, Harvard Medical School; and visiting professor of pathology, University of Oxford-Lincoln College, New York City. For pioneering the use of molecular assays in diagnostic pathology and establishing the concept of “metabolic oncogenes” in the development of cancer. This discovery has led to clinical trials targeting lipogenic enzymes in prostate cancer.

Beatriz Luna, PhD, Staunton Distinguished Professor of Psychiatry and Pediatrics and professor of psychology, bioengineering, and radiology, University of Pittsburgh School of Medicine, Pittsburgh. For establishing a model of normative adolescent neurocognitive development, identifying neural mechanisms of plasticity supporting the specialization into adulthood of cognitive and motivational systems; informing AMA briefs for the U.S. Supreme Court decisions on juvenile sentencing; and the creation and leadership of the Flux Society for Developmental Cognitive Neuroscience.

Trudy F.C. Mackay, PhD, FRS, director, Center for Human Genetics, Self Family Endowed Chair of Human Genetics, and professor of genetics and biochemistry, Clemson University, Greenwood, S.C. For being recognized as one of the world’s leading geneticists for pioneering studies on the genetic architecture of complex traits and the discovery of fundamental principles of quantitative genetics with broad applications for medicine.

Nicole Maestas, MPP, PhD, John D. MacArthur Professor of Health Care Policy, Harvard Medical School, Boston. For contributions to our understanding of the economics of employment, work capacity, and income support for people who are disabled or elderly; for national leadership in building the evidence base for disability policymaking; and for contributions to the economics of health insurance for the elderly and people with disabilities.

David J. Mangelsdorf, PhD, professor and chair, department of pharmacology, and investigator, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas. For landmark discoveries of oxysterol (LXRs) and bile acid (FXR) nuclear receptors that revealed the sensing mechanisms that govern reverse cholesterol transport and bile acid synthesis. He co-discovered the key roles of the endocrine hormones FGF21 and FGF15/19 in regulating lipid and energy metabolism, and bile acid homeostasis, respectively.

Jeanne Marrazzo, MD, MPH, director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. For leading transformative research that has redefined our understanding of relationships between the vaginal microbiome and female reproductive tract infections, HIV pre-exposure prophylaxis (PrEP), hormonal contraception, and risk of STI/HIV acquisition. She has had key roles in NIH-funded networks — Infectious Diseases Clinical Research Consortium and HIV Prevention Trials.

Erica Elizabeth Marsh, MD, MSCI, S. Jan Behrman Collegiate Professor of Reproductive Medicine, vice chair and division chief, reproductive endocrinology and infertility, department of obstetrics and gynecology, University of Michigan Medical School, Ann Arbor. For research on uterine leiomyomas and for her efforts to eliminate disparities in reproductive health. Her commitment to building research capacity in women’s health, both nationally and globally, and her cultivation of the next generation of leaders in reproductive health will have a lasting impact.

Dayna Bowen Matthew, JD, PhD, dean and Harold H. Greene Professor of Law, George Washington University Law School, Washington, D.C. For advancing our understanding of how policies and legal systems have produced health inequities. Her work has resulted in actionable federal policy changes in the United States.

Margaret M. McCarthy, PhD, director, University of Maryland – Medicine Institute for Neuroscience Discovery; and James and Carolyn Frenkil Dean’s Endowed Professor and distinguished university professor, department of pharmacology, physiology, and drug development, University of Maryland School of Medicine, Baltimore. For being the first to discover a critical role of the immune system in determining sex differences and the impact of infection and inflammation on neuroanatomical and behavioral outcomes, which provided mechanistic insights into the higher prevalence of autism spectrum disorders and schizophrenia in boys and men.

Genevieve B. Melton-Meaux, MD, PhD, senior associate dean, health informatics and data science; director, Center for Learning Health System Sciences; and professor of surgery and health informatics, University of Minnesota, Minneapolis. For research in integrating AI with health care, bridging surgery and informatics, and fueling learning health systems. Melton-Meaux explores complex health dynamics, from optimizing clinical note usage in electronic health records to large-scale detection of social/behavioral health determinants with clinical data. Her work has significantly advanced biomedical informatics, clinical practice, and policy.

Dan Merenstein, MD, professor and director of research programs of family medicine, Georgetown University School of Medicine, and department of human science, Georgetown University School of Health, Washington, D.C. For being an accomplished large-scale clinical trialist in family medicine. His work is inspired by practice and teaching, engaging hundreds of busy primary care practices in real-world research, answering foundational questions that inform daily practice.

Funda Meric-Bernstam, MD, professor and chair, department of investigational cancer therapeutics, University of Texas MD Anderson Cancer Center, Houston. For leading practice-changing clinical oncology trials in human epidermal growth factor receptor 2 (HER2)-targeted therapy, bringing novel biomarker-driven combination therapies from bench to bedside. She is leading large-scale national efforts in precision oncology such as NCI ComboMATCH and investigator-initiated antibody drug conjugate-MATCH; and leads one of the most influential developmental therapeutics programs in the world.

Matthew J. Miller, MD, MPH, ScD, professor, department of public health and health sciences, Northeastern University, Boston. For being a nationally recognized researcher who has led foundational epidemiological research on firearm access and suicide, enhanced our understanding of the theoretical underpinnings of suicide prevention via lethal means restriction, and developed clinical interventions illuminating how counseling patients and their families for reducing access to firearms can save lives.

Julie Morita, MD, president and chief executive officer, The Joyce Foundation, Chicago. For being one of the nation’s most respected public health leaders, who has dedicated her career to advancing health equity. During 20 years in Chicago, she addressed racial and ethnic health disparities, leading implementation of the city’s first health equity plan. Previously, as the Robert Wood Johnson Foundation’s executive vice president, she led strategic planning efforts to ensure all programming focuses on addressing health and racial equity.

Sally C. Morton, PhD, executive vice president, Knowledge Enterprise; and professor of statistics, College of Health Solutions and School of Mathematical and Statistical Sciences, Arizona State University, Tempe. For preeminent leadership in statistics, health policy, and science in both academic and nonprofit research institutions; excellence in evidence synthesis of clinical and public health issues; and impactful methodology in patient-centered comparative effectiveness research. Her pioneering contributions to clinical practice guidelines and health care interventions have reduced morbidity and mortality.

Niki Maria Moutsopoulos, DDS, PhD, senior investigator, Intramural Research Program, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Md. For making seminal contributions toward understanding and treating the prevalent human oral disease periodontitis. Her laboratory has contributed to the understanding of both homeostatic and pathogenic inflammation in the oral cavity, informing interventions for both rare and common forms of aggressive forms of periodontal disease.

Avindra Nath, MD, chief, Section of Infections of the Nervous System, and clinical director, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Md. For pioneering research and strong leadership in emerging and persistent infections of the nervous system by studying pathophysiology, developing treatments, and conducting clinical studies. This includes retroviruses, Ebola, Zika, nodding syndrome, and COVID-19 as well as Long COVID, ME/CFS, and Gulf War syndrome.

Jennifer B. Nuzzo, DrPH, SM, director, Pandemic Center, Brown University School of Public Health, Providence, R.I. For co-creating the Global Health Security Index and conducting research to measure and improve national preparedness for infectious disease threats. She co-established a global COVID-19 testing data tracker and created a health systems resilience checklist for biological emergencies.

Santa Jeremy Ono, PhD, president, University of Michigan, Ann Arbor. For his work as a molecular immunologist who has studied the regulation of the immune response and the pathogenesis of age-related macular degeneration. He is a recognized leader in higher education who has served as the president of the University of Cincinnati, the University of British Columbia, and now as the 15th president of the University of Michigan.

David Pellman, MD, Howard Hughes Medical Institute investigator and professor of cell biology and pediatrics, Dana-Farber Cancer Institute and Harvard Medical School, Boston. For identifying the mechanistic basis for mutational processes that generate a large fraction of the structural and numerical chromosome abnormalities in cancer and certain congenital diseases. In particular, his discovery of a mechanism explaining chromothripsis is considered a landmark in cancer genetics.

Priscilla Eyikojoka Pemu, MD, MS, FACP, FAHA, professor of medicine, department of medicine, Morehouse School of Medicine, Atlanta. For pioneering work on clinical trial diversity, centering on the importance of regaining trust, fostering transparent collaboration, and ensuring the equitable participation of diverse populations in medical research, from Grady health system, a large public hospital, to primary care practices, historically black churches and institutions.

Mary L. Phillips, MD (Cantab), Pittsburgh Foundation-Emmerling Endowed Chair in Psychotic Disorders and professor in psychiatry, department of psychiatry, University of Pittsburgh, Pittsburgh. For use of state-of-the-art neuroimaging and translational approaches to study neurobiological processes predisposing to bipolar disorder and depression. She has identified biomarkers reflecting these processes to help improve early diagnosis and risk identification in youth, and guide novel neuromodulation treatment developments to improve mental health and functional outcomes for these disorders.

Olivier Pourquié, PhD, Frank Burr Mallory Professor, department of pathology, Brigham and Women’s Hospital, and department of genetics, Harvard Medical School, Boston. For his discovery of the segmentation clock and landmark work on vertebral development that provides a framework to understand pathologies of the spine such as scoliosis or spina bifida. He is recognized worldwide as a leader in developmental biology and in the use of human stem cells for disease modeling and regeneration of the musculoskeletal system.

Mark R. Prausnitz, PhD, Regents’ Professor, School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta. For innovating on research advancing microneedles and other drug delivery technologies, inventing novel pharmaceutical methods and devices, translating drug delivery technology into clinical trials and medical products, bringing medical advances to patients by founding companies, inspiring students to be creative and impactful engineers, and providing leadership among his colleagues.

Uma M. Reddy, MD, MPH, professor and vice chair of research, department of obstetrics and gynecology, Vagelos College of Physicians and Surgeons, and professor of population and family health, Mailman School of Public Health, Columbia University Irving Medical Center, New York City. For leadership of paradigm-shifting research that has fundamentally advanced the understanding of stillbirth, neonatal morbidity and mortality, and labor management and their impact on maternal morbidity through large multicenter cohorts and trials, driving new standards in national obstetric practice and improved outcomes for pregnant people and their children.

Juergen Albrecht Richt, DVM, PhD, Regents and University Distinguished Professor of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan. For being a pioneer in infectious diseases of “One Health” importance. His prolific basic and translational research findings on emerging pathogens of livestock, wildlife, and humans are unique and highly significant for animal/public health. His biocontainment expertise is crucial for the nation’s bio- and agro-terrorism defense capacities.

Selwyn O. Rogers Jr., MD, MPH, FACS, MAMSE, Dr. James E. Bowman Jr. Professor of Surgery; chief, Section for Trauma and Acute Care Surgery; founding director, Trauma Center; and executive vice president for community health engagement, University of Chicago Medicine, Chicago. For paradigm-shifting hospital-based violence interventions including Medical-Legal Clinics that address the social drivers of violent trauma to reduce gun violence and reduce recidivism. He is a leading national advocate for a holistic public health approach with an equity lens to prevent firearms injuries.

Jeffrey D. Rothstein, MD, PhD, John W. Griffin Director, Brain Science Institute; professor of neurology and neuroscience; and director, Robert Packard Center for ALS Research, Johns Hopkins University School of Medicine, Baltimore. For discoveries that led to the first FDA-approved drug for amyotrophic lateral sclerosis (ALS), and antisense therapies for C9orf72 ALS/FTD and nuclear pore dysfunction for TDP-43 based neurodegeneration. He founded the Packard Center 25 years ago, which has advanced science and training of leading basic and clinical ALS researchers.

David Henry Rowitch, MD, PhD, FMedSci, FRS, professor and head, department of pediatrics, University of Cambridge; adjunct professor of pediatrics, University of California, San Francisco; and associate director, Basic and Translational Research, Cedars-Sinai Guerin Children’s, Cambridge, United Kingdom. For establishing fundamental genetic mechanisms that determine glial cell development in the brain. His research has provided insight into causes of leukodystrophy, multiple sclerosis, and cerebral palsy. He has transformed our understanding of fundamental neuroscience and promoted important advances for human neurological diseases.

Dana Gelb Safran, ScD, president and chief executive officer, National Quality Forum; and chief scientific officer, The Joint Commission, Washington, D.C. For leadership, innovation, and accomplishment in improving health care quality, outcomes, equity, and affordability through performance measurement, including as an architect of value-based payment models that catalyzed payment reform nationally and internationally, and as a pioneer of patient-reported measures and novel consensus-based methods to rationalize and improve quality and implementation science.

Christine E. Schmidt, PhD, distinguished professor and J. Crayton Pruitt Family Endowed Chair, J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville. For outstanding leadership, pioneering research, and clinical translation in neural tissue engineering and wound healing.

Nina F. Schor, MD, PhD, deputy director for intramural research, Office of the Director, National Institutes of Health, Bethesda, Md. For pioneering research that has radically improved outcomes for children with tumors of the nervous system. She has been a role model, mentor, and beacon to countless other female physician-scientists throughout her amazing career, from bench scientist to academic dean to NIH leader.

Deborah Schrag, MD, MPH, chair, department of medicine, Memorial Sloan Kettering Cancer Center, New York City. For pioneering efforts to develop, validate, and disseminate methods for ascertaining patient-reported outcomes that have advanced the quality, effectiveness, and efficiency of cancer research, for bridging the efficacy-effectiveness gap by developing strategies to improve equitable delivery of cancer care, and for leading practice changing studies in colorectal cancer.

Eugenia South, MD, MSHP, Ralph Muller Presidential Associate Professor, Perelman School of Medicine; associate vice president of health justice, University of Pennsylvania Health System; and faculty director, Center for Health Justice, University of Pennsylvania, Philadelphia. For being among the country’s foremost leaders in developing and testing interventions to dismantle structural racism and prevent firearm injury in Black neighborhoods. She has made substantive, field-changing scientific and real-world contributions to advancing health via the lens of racial, environmental, and economic justice.

Konstantina M. Stankovic, MD, PhD, FACS, Bertarelli Foundation Professor and chair, department of otolaryngology – head and neck surgery, Stanford University School of Medicine, Stanford, Calif. For expertise in the causes and treatments of hearing loss, which affects 1.5 billion people worldwide. She has initiated and led successful national and international collaborations to develop and deploy novel molecular diagnostics and therapeutics for hearing loss while educating tomorrow’s leaders in surgery and science.

David M. Studdert, LLB, ScD, MPH, professor of health policy, department of health policy, Stanford University School of Medicine, and professor of law, Stanford Law School, Stanford, Calif. For illuminating the relationship between gun ownership and increased mortality risk. His landmark studies of medical injury and malpractice litigation, which produced novel evidence of how the liability system relates to health care quality, have deeply influenced legal reform.

Lorenz Studer, MD, director, Center for Stem Cell Biology, and member, Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York City. For pioneering methods to differentiate mouse and human stem cells into a wealth of diverse nervous system cells. He discovered strategies to direct cellular maturation and aging, transforming our ability to model neurodegenerative diseases. He has spearheaded a human stem cell-based transplantation therapy for Parkinson’s disease.

Alexis A. Thompson, MD, MPH, chief, Division of Hematology, and Elias Schwartz MD Endowed Chair in Hematology, Children’s Hospital of Philadelphia; and professor of pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia. For leadership in sickle cell disease (SCD), including creation of the first national SCD learning community, the largest SCD data repository, and collaborations to improve care for children with SCD in sub-Saharan Africa, and for her role in recent FDA approval of gene therapy and other novel SCD therapeutics.

Matthew G. Vander Heiden, MD, PhD, director, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge. For leadership in understanding cell metabolism and how it influences cancer initiation, progression, and therapy responses. His work has contributed to the development of approved therapies for cancer and anemia, and he is thought leader in understanding metabolic phenotypes and their relations to disease pathogenesis.

Fan Wang, PhD, professor of brain and cognitive sciences and investigator, McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge. For discoveries of brain circuits important for anesthesia and analgesia, and circuits for generating rhythmic and coordinated orofacial movements. Her research provided foundational knowledge for developing new therapies to treat chronic pain and movement disorders.

Donna L. Washington, MD, MPH, director, Health Equity-QUERI National Partnered Evaluation Center, Veterans Health Administration; and professor of medicine, VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at University of California, Los Angeles. For groundbreaking research that has enhanced the understanding of the health and health care needs of U.S. veterans and to ensure equitable access to the highest quality health care and outcomes for this diverse population. Her work informs health policy and strategic-planning initiatives to eliminate health disparities by sex, race, and ethnicity.

Mitchell J. Weiss, MD, PhD, chair, department of hematology, and Arthur Nienhuis Endowed Chair in Hematology, St. Jude Children’s Research Hospital, Memphis, Tenn. For being a key leader in characterizing blood cell development and the pathogenesis of red cell diseases, which has defined roles for noncoding RNAs in hematopoiesis and identified alpha-hemoglobin-stabilizing protein (AHSP) as a key regulator of alpha globin folding. He applied embryonic stem and induced pluripotent stem cell technologies to study erythropoiesis and develop new approaches to therapy.

E. John Wherry III, PhD, Schiffrin President’s Distinguished Professor and chair, department of pharmacology and translational therapeutics; and director, Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia. For pioneering the field of T cell exhaustion in chronic infections and cancer where he conducted a deep molecular dissection of this immune biology. He defined the genetic and epigenetic signatures of immunity and the mechanisms of blocking the PD1 immune checkpoint, the basis of major advances in cancer treatment.

Garen J. Wintemute, MD, MPH, Susan P. Baker and Stephen P. Teret Chair in Violence Prevention, department of emergency medicine, University of California, Davis, Sacramento. For being a leading researcher in firearm injury prevention, spanning five decades. He brilliantly translates research findings to inform and evaluate gun violence policies and initiatives that are the basis of major policies at the state and federal levels.

Hao Wu, PhD, senior investigator, Program in Cellular and Molecular Medicine, Boston Children’s Hospital; and Asa and Patricia Springer Professor, department of biological chemistry and molecular pharmacology, Harvard Medical School, Boston. For discovering supramolecular complexes (signalosomes) as central organizing structures that mediate signal transduction in innate immunity. Her studies led to a paradigm shift in signal transduction and new therapeutic strategies for inflammation and cancer where small molecules are developed to keep the signaling proteins in a monomeric, inactive state.

Marc A. Zimmerman, PhD, Marshall H. Becker Collegiate Professor, department of health behavior and health education, University of Michigan School of Public Health, Ann Arbor. For recognition as a preeminent leader for the development and implementation of groundbreaking public health interventions to prevent community and firearm violence.

Newly elected international members and their election citations are:

Jarbas Barbosa da Silva Jr., MD, MPH, PhD, director, Pan American Health Organization, Washington, D.C. For making important contributions as the head of Brazil’s health surveillance and regulatory authority. As director of the Pan American Health Organization, he brings a relevant regional perspective to health equity.

Kelly Chibale, PhD, professor of organic chemistry, department of chemistry; and founder and director, Holistic Drug Discovery and Development Center, University of Cape Town, Cape Town, South Africa. For pioneering infectious disease drug discovery on the African continent. He has led international project teams including one that discovered the first small molecule clinical candidate for any disease, researched on African soil by an African-led international team.

George Coukos, MD, PhD, director, oncology department, Lausanne University Hospital; and director, Ludwig Institute for Cancer Research Lausanne Branch, Lausanne, Switzerland. For discovering the correlation between T-cell infiltration and favorable prognosis in ovarian cancer, an observation later generalized to all human tumors. He also uncovered that tumor vasculature is a barrier to immunotherapy, leading to treatments with angiogenesis inhibitors and immune checkpoint blockade showing significant benefit in many tumors.

Nicholas Peter Franks, PhD, professor of biophysics and anaesthetics, department of life sciences, Imperial College London, London, United Kingdom. For revolutionary discoveries that have shaped our understanding of how anaesthetics work. He overturned the long-held assumption that anaesthetics interact nonspecifically with cell membranes, demonstrating that they act at specific binding sites on a small number of receptors.

Thumbi Ndung’u, BVM, PhD, director for basic and translational science, Africa Health Research Institute; professor and Victor Daitz Chair, HIV Pathogenesis Programme, University of KwaZulu-Natal; and professor of infectious diseases, University College London, Durban, South Africa. For generating the first primary isolate infectious molecular clone of HIV-1 subtype C, enabling research on viral-host mechanisms of pathogenesis. He has identified regions of immune vulnerability in HIV-1 subtype C for candidate vaccine and immunotherapeutic development, currently leading the first HIV cure trial in Africa.

Friday Ebhodaghe Okonofua, MD, BSc, MB ChB, PhD, FRCOG, FMCOG, FWACS, FICS, center leader, African Center of Excellence in Reproductive Health Innovation, University of Benin, Benin City, Nigeria. For expertise in reproductive health and leading large national and international research in interventional and implementation research for preventing maternal mortality with impact on policies and programming in African countries. He is committed to gender quality, ethics, and equity in global and Africa settings.

Aziz Sheikh，OBE，F(xiàn)RSE，F(xiàn)MedSci， 牛津大學(xué)初級保健健康科學(xué)納菲爾德教授兼納菲爾德初級保健健康科學(xué)系主任;以及英國愛丁堡大學(xué) Usher 研究所教授兼主任。成為健康信息學(xué)和數(shù)據(jù)科學(xué)領(lǐng)域的全球領(lǐng)導(dǎo)者，在國際上提高臨床護理的質(zhì)量、安全性和效率。他是哮喘護理和初級保健領(lǐng)域的世界領(lǐng)導(dǎo)者，并幫助領(lǐng)導(dǎo)了蘇格蘭的 COVID 應(yīng)對工作。

珍妮特·凱瑟琳·斯邁利 （Janet Kathleen Smylie），醫(yī)學(xué)博士、公共衛(wèi)生碩士、FCFP，研究科學(xué)家、專職醫(yī)師和多倫多團結(jié)健康 - 圣邁克爾斯醫(yī)院 Well Living House 行動研究中心主任;和加拿大多倫多大學(xué) Dalla Lana 公共衛(wèi)生學(xué)院和家庭與社區(qū)醫(yī)學(xué)系教授。因?qū)?chuàng)新研究轉(zhuǎn)化為土著社區(qū)的切實利益而受到全球尊重。貢獻包括推進土著知識翻譯、揭露城市土著健康不平等以及提高對衛(wèi)生系統(tǒng)應(yīng)對種族主義的反應(yīng)的認識。

Henrik Toft Sørensen，醫(yī)學(xué)博士，博士，DrMedSci，DrSci，丹麥奧胡斯大學(xué)臨床流行病學(xué)系教授兼系主任。開拓?zé)o與倫比的丹麥數(shù)據(jù)系統(tǒng)之間的聯(lián)系，包括醫(yī)療記錄、處方、疾病登記和/或生物樣本。他塑造了信息系統(tǒng)，使基于這些系統(tǒng)的 1,400 項研究成為可能，為包括癌癥在內(nèi)的常見疾病的結(jié)果和臨床過程提供了開創(chuàng)性的啟示。

Sarah J. Tabrizi，博士，MBChB，F(xiàn)MedSci，F(xiàn)RS，臨床神經(jīng)學(xué)和神經(jīng)遺傳學(xué)教授，亨廷頓病中心主任，倫敦大學(xué)學(xué)院皇后廣場神經(jīng)病學(xué)研究所神經(jīng)退行性疾病系聯(lián)合主任;和首席研究員，英國倫敦 UK Dementia。由于對亨廷頓病實驗性治療做出了貢獻，領(lǐng)導(dǎo)多學(xué)科研究團隊進行了核酸治療的首次隨機臨床試驗，并建立了一種與基礎(chǔ)科學(xué)和患者研究相關(guān)的生物分期方法，用于治療神經(jīng)退行性疾病，類似于癌癥治療。